"Revolutionary Wonder Drug Offers Breakthrough Treatment for Deadly Cancers"
Researchers at Queen Mary University of London have developed a new drug, ADI-PEG20, which has shown promising results in treating mesothelioma, a hard-to-treat and aggressive form of cancer linked to asbestos exposure. The drug, which works by cutting off the tumor's food supply, has quadrupled three-year survival rates and increased average survival by 1.6 months. The study, published in JAMA Oncology, involved 249 patients and found that those who received the new drug alongside chemotherapy survived for an average of 9.3 months, compared to 7.7 months for those who had a placebo and chemotherapy. This breakthrough offers hope to patients with mesothelioma and represents the first successful combination of chemotherapy with a drug that targets cancer's metabolism developed for this disease in 20 years.
